ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

New antibiotic company formed

February 6, 2006 | APPEARED IN VOLUME 84, ISSUE 6

Novartis' Sandoz unit has spun off its antibiotic R&D operations into a new company, Nabriva, which will be fueled by $50 million in financing from Nomura Phase4 Ventures, Global Life Science Ventures, the Wellcome Trust, HBM Partners, and Novartis' venture capital arm. Sandoz says the R&D operation didn't fit with its focus on generics. Nabriva will develop small-molecule antibiotics for use against community and hospital infections. Its pipeline of antibacterial drugs includes three late preclinical projects and one product about to enter Phase I trials.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment